These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 31076057)

  • 41. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel monoclonal treatments in severe asthma.
    Meteran H; Meteran H; Porsbjerg C; Backer V
    J Asthma; 2017 Dec; 54(10):991-1011. PubMed ID: 28287273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.
    Jackson DJ; Korn S; Mathur SK; Barker P; Meka VG; Martin UJ; Zangrilli JG
    Drug Saf; 2020 May; 43(5):409-425. PubMed ID: 32242310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biologics for oral corticosteroid-dependent asthma.
    Yılmaz İ
    Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
    [No Abstract]   [Full Text] [Related]  

  • 45. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.
    Pelaia C; Calabrese C; Vatrella A; Busceti MT; Garofalo E; Lombardo N; Terracciano R; Pelaia G
    Biomed Res Int; 2018; 2018():4839230. PubMed ID: 29862274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biologics in severe asthma.
    Pelaia C; Pelaia G; Crimi C; Longhini F; Lombardo N; Savino R; Sciacqua A; Vatrella A
    Minerva Med; 2022 Feb; 113(1):51-62. PubMed ID: 33555158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Monoclonal Antibodies for Treatment of Uncontrolled Eosinophilic Asthma.
    Koski RR; Grzegorczyk KM
    J Pharm Pract; 2020 Aug; 33(4):513-522. PubMed ID: 31046541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma.
    Kupczyk M; Kuna P
    Immunotherapy; 2018 Apr; 10(5):349-359. PubMed ID: 29359607
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Current State of Biologic Therapies for Treatment of Refractory Asthma.
    Mavissakalian M; Brady S
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):195-207. PubMed ID: 31981048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
    Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
    Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation.
    Uller L; Mathiesen JM; Alenmyr L; Korsgren M; Ulven T; Högberg T; Andersson G; Persson CG; Kostenis E
    Respir Res; 2007 Feb; 8(1):16. PubMed ID: 17328802
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Biologicals in the Treatment of Bronchial Asthma].
    Haasler I; Taube C
    Pneumologie; 2017 Oct; 71(10):684-698. PubMed ID: 29017221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity of biologics used in the treatment of asthma.
    Neunie OAM; Rabbani W; Baker D; Chambers ES; Pfeffer PE; Kang AS
    Hum Antibodies; 2024; 32(3):121-128. PubMed ID: 38905039
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
    Bel EH; Ten Brinke A
    Chest; 2017 Dec; 152(6):1276-1282. PubMed ID: 28583618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fevipiprant in the treatment of asthma.
    White C; Wright A; Brightling C
    Expert Opin Investig Drugs; 2018 Feb; 27(2):199-207. PubMed ID: 29363343
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
    Noga O; Hanf G; Brachmann I; Klucken AC; Kleine-Tebbe J; Rosseau S; Kunkel G; Suttorp N; Seybold J
    J Allergy Clin Immunol; 2006 Jun; 117(6):1493-9. PubMed ID: 16751018
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment.
    Chevalier E; Stock J; Fisher T; Dupont M; Fric M; Fargeau H; Leport M; Soler S; Fabien S; Pruniaux MP; Fink M; Bertrand CP; McNeish J; Li B
    J Immunol; 2005 Aug; 175(4):2056-60. PubMed ID: 16081770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
    J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells.
    Xue L; Barrow A; Pettipher R
    Clin Exp Immunol; 2009 Apr; 156(1):126-33. PubMed ID: 19220324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.